In a patient with a history of two episodes of HSV‑1 viral meningitis, should she keep acyclovir on hand and take it prophylactically at the first sign of fever or flu‑like symptoms, or should antiviral therapy be initiated only after symptoms develop?

HSV-1 Meningitis Prophylaxis Strategy

For a patient with recurrent HSV-1 meningitis, keeping acyclovir on hand for early self-initiated treatment at the first sign of fever or flu-like symptoms is a reasonable harm-reduction strategy, though formal evidence supporting this specific approach is limited.

The Evidence Landscape

The available guidelines do not directly address prophylactic or early self-initiated treatment for recurrent HSV meningitis. The 1999 USPHS/IDSA guidelines explicitly state that "prophylaxis of initial episodes of HSV disease is not recommended" and note that "chronic therapy with acyclovir is not required after lesions resolve" 1. However, these recommendations were written primarily for genital HSV and HIV-infected populations, not for the specific scenario of recurrent HSV meningitis.

Key Clinical Distinctions

HSV meningitis is fundamentally different from HSV encephalitis:

• HSV meningitis is typically self-limited with excellent outcomes in immunocompetent patients 2
• HSV encephalitis carries 70% mortality without treatment, reduced to 20-30% with acyclovir 3, 4
• The urgency of treatment differs dramatically between these conditions

What the Research Shows

The most relevant study for your patient's situation is the 2012 randomized controlled trial that evaluated valacyclovir 500 mg twice daily for suppression after HSV-2 meningitis 5. This study found:

• Suppressive therapy at this dose did NOT prevent recurrent meningitis
• Paradoxically, there was a rebound phenomenon with increased recurrence risk after stopping the medication (hazard ratio 3.29)
• The dose was likely too low for CNS penetration
• One-third of patients experienced 1-4 recurrences during the study period

However, a 2015 retrospective study provides nuanced insight 2:

• Immunocompetent patients with HSV meningitis had no neurologic sequelae regardless of treatment
• Immunocompromised patients showed improved outcomes with antiviral therapy (P < 0.05)
• Most patients rapidly improved with or without treatment

A 2026 case report describes exactly your patient's strategy 6: A patient with recurrent HSV-2 meningitis adopted self-initiated episodic oral antiviral therapy at symptom onset, which appeared to attenuate clinical severity.

Practical Recommendation Algorithm

For your immunocompetent patient with recurrent HSV-1 meningitis:

1. Keep oral acyclovir or valacyclovir readily available at home
2. At the first sign of fever, headache, or flu-like symptoms:
   • Start oral valacyclovir 1000 mg three times daily (higher CNS penetration than the failed 500 mg twice daily dose) 7
   • OR acyclovir 400 mg five times daily 8
3. Seek immediate medical evaluation if:
   • Confusion or altered mental status develops (suggests encephalitis, not meningitis)
   • Severe headache with photophobia persists beyond 24-48 hours
   • Symptoms worsen despite oral antivirals
4. Continue oral therapy for 7-10 days if symptoms resolve quickly
5. Do NOT use continuous daily suppressive therapy given the rebound risk demonstrated in the RCT 5

Important Caveats

Distinguish meningitis from encephalitis:

• Meningitis: fever, headache, photophobia, neck stiffness, normal mental status
• Encephalitis: altered mental status, confusion, behavioral changes - requires immediate IV acyclovir 4, 9

Renal function monitoring:

• Acyclovir can cause reversible nephrotoxicity in up to 20% of patients on IV therapy 3
• Maintain adequate hydration during oral treatment 8
• Less concern with oral therapy but still relevant

The evidence gap:

• No high-quality studies specifically address early self-initiated treatment for recurrent HSV meningitis
• The approach is extrapolated from genital herpes episodic therapy principles 10
• Case reports suggest feasibility 6, 11

Why This Approach Makes Sense

Given that:

• HSV meningitis in immunocompetent patients is self-limited 2
• Early treatment of genital HSV recurrences shows benefit when started during prodrome 10
• Your patient has established recurrent disease with recognizable prodromal symptoms
• The risk of oral acyclovir is minimal compared to potential benefit
• Delayed treatment correlates with worse outcomes in HSV encephalitis 9

The harm-reduction strategy of having medication available for early self-initiation is clinically prudent, even without Level A evidence specifically for this indication. This represents practical application of available evidence to a rare clinical scenario where formal trials are unlikely to ever be conducted.